Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review

Xiaofeng Chen(Ningbo University), Yongqian Shu(Jiangsu Province Hospital), Lingjun Zhu(Henan University), Yongmei Yin(Jiangsu Cancer Hospital), Yiqian Liu(Jiangsu Province Hospital), Oluf Dimitri Røe(Norwegian University of Science and Technology), Yingying Qian(Nanjing Medical University), Renhua Guo(Sun Yat-sen University)

PLoS ONE

March 21, 2013

10.1371/journal.pone.0059314

Cited by 62

Related Papers

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

|The Lancet Respiratory Medicine|2020|508

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

|BMJ|2022|494

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

|Annals of Oncology|2019|475

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

|Journal of Clinical Oncology|2021|350

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

|Journal of Thoracic Oncology|2021|311